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Abstract:
Objective: To compare the ability of MRI taken before and after 
neo-adjuvant treatment in locally advanced rectal cancer (LARC) to 
predict the necessity of extended total mesorectal excision and to 
evaluate the use of histopathological tumour regression grade 
(TRG).  
Methods: Prospective registration of 92 MRI evaluated T4a cancers 
undergoing elective surgery between 2002 and 2007 in a tertiary 
referral centre for multimodal treatment of rectal cancer.   
Results: MRI identifies LARC patients in need of neo-adjuvant 
treatment. MRI predicted T downstaging in 10% and N downstaging 
in 59%. After extended total mesorectal excision in 95% of 
patients, mostly en-bloc resections, 79% R0 resections, 18% R1 
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and 3% R2 were obtained. N- and T-stage downstaging occurred in 
59% and 10% evaluated by yMRI. There was a linear trend with 
higher TRG in higher ypT-stage (p&lt;0.01). Preoperative chemo 
radiotherapy resulted in a higher percent of patients obtaining 
TRG1-3 compared to patients receiving radiotherapy (79% vs 57%, 
p=0.02). The pelvic wall was the area of failure in 70% of the R1 
resections in M0 patients.  
Conclusion: MRI after neo-adjuvant treatment did not predict 
downstaging satisfactorily with tumour cells remaining within areas 
of fibrosis (TRG2-3) in 55% of the pT4 patients. Therefore, if a R0 
resection is the goal, we advocate the optimal surgery in 
accordance with the pre-treatment MRI. The study has initiated a 
new approach to histopathological classification of the removed 
specimen where we introduce a MRI assisted technique for 
investigating the areas at risk outside the mesorectal fascia in the 
specimen. 
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INTRODUCTION
Total mesorectal excision (TME) is widely accepted as the procedure of choice in rectal 
cancer surgery (1;2). TME has increased long-term survival and reduced local 
recurrence in general (2;3). In cases with microscopic positive resection margins 
however, the recurrence rate has been reported to be as high as 80% (4). 
Recurrence of locally advanced rectal cancer (LARC) is reduced by preoperative 
radiotherapy (RT) or chemo radiation therapy (CRT) (5;6), and the 5-year survival of 
LARC has now increased to more than 50% (7;8). 
The surgical strategy in LARC is based on TME but modified to include tumour-suspect 
tissue outside the mesorectal plane. To plan such an extended TME (ETME) the 
surgeon needs as accurate preoperative information as possible about the 
extensiveness of the malignant process. Preoperative magnetic resonance imaging 
(MRI) is considered the best investigative tool for evaluation of rectal cancer (9-11) and 
LARC (12), due to superior demonstration of signal differences between fat and soft 
tissue. MRI’s value in identifying tumour infiltration into neighbouring organs and the 
ability to demonstrate neo-adjuvant downstaging has not been firmly established.
Preoperative CRT will in the majority of cases reduce tumour size. We are aware 
of only one single report (abstract) evaluating MRI before and after neo-adjuvant 
therapy in clinical/ radiological T4 cases (n=53) (13). No reports seem to study if 
the repeat MRI after neo-adjuvant treatment improves the surgical achievement.  
We have compared the clinical ability of MRI taken before and after CRT to predict 
the necessary extension of the TME procedure in LARC, the possibility to achieve 
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a R0 resection and evaluated the use of histopathological tumour regression grade 
(TRG). 
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MATERIALS AND METHODS
The Radiumhospitalet Cancer Center is a tertiary referral centre for multimodal 
treatment of LARC and locally recurrent rectal cancer. In the period from January 2002 
until April 2007, 268 patients with primary rectal adenocarcinoma 0-15 cm from the anal 
verge were included in our prospective database (approved by the Ethical Committee at 
the University of Oslo). Judged on MRI 99 patients had T3 tumours (invading muscularis 
propria but not peritoneum or perirectal tissue), 28 had T1-2 tumours and did not 
receive RT and 26 patients had T4b (involving the peritoneal reflection but not 
neighbouring organs).  The remaining 115 had T4a rectal cancer penetrating the 
mesorectal fascia and invading other organs or structures. Seven of these did not 
receive pelvic RT or the treatment was stopped before they had received 50 Gy. 
Another eight patients were not evaluated with MRI both before and after RT, four had 
MRI of suboptimal quality, and three patients were surgically explored and found 
inoperable due to abdominal carcinomatosis or to extensive liver metastases. One 
patient was excluded due to previous history of pelvic malignancy. Known metastatic 
disease (n=18) was not an exclusion criterion by itself. Thus 92 patients with T4a rectal 
cancer with neo-adjuvant treatment were included in the study. The staging workup 
included endoscopy, biopsy, digital exploration and bimanual palpation in general 
anaesthesia before and after RT.
Stage evaluation
The TNM system classifies carcinomas according to depth of invasion of the primary 
tumour, presence of regional lymph node metastases and distant metastases. T- and N-
stages were evaluated by MRI both before (cmrT, cmrN) and after neo-adjuvant therapy 
(ymrT, ymrN) as well as after histopathological examination (ypT, ypN) (14). We have 
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preferred to record the R stage as local R stage judged by the removed specimen (R0 = 
microscopically free circumferential and distal margins, R1 = microscopically involved 
margins  1 mm from resected margin and R2 = macroscopic residual cancer in the 
pelvis or no resection). 
Magnetic resonance imaging 
The treatment of rectal cancers varies according to tumour stage. Three specialists in 
gastrointestinal radiology performed all investigations with the same MRI technique and 
validated protocols as they used in the MERCURY study (10;11). Evaluation of lymph 
nodes followed the criteria developed by Brown (15). All patients were discussed at the 
multidisciplinary staff meeting and one of the radiologists (HLE) crosschecked all data. 
The patients had two investigations, the first before neo-adjuvant therapy (cMRI) and 
the second at a median of 33 days (range 18 – 91 days) after completed treatment 
(yMRI). We considered a MRI distance of >1 mm from tumour tissue to surrounding 
structures necessary to avoid resection of any structure or organ. A distance  1 mm to 
an organ or a structure was characterized as threatening the organ or structure.  
However, a structure was evaluated on MRI as infiltrating an organ or structure only if 
the tumour grew into it. After CRT change of tumour T2-signal to low as in fibrosis was 
mostly evaluated as potential residual tumour, according to the radiologist’s awareness 
of the difficult detection of small islets of tumour within fibrosis.
MRI was performed using a 1.5-T MR scanner and phased-array coil. Two-dimensional 
fast spin-echo sequences were preformed. High-resolution T2W images were obtained 
in a plane perpendicular to the mesorectum at the site of tumour and suspicious lymph 
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nodes. In addition, high-resolution T2W images were obtained in coronal planes in low 
rectal cancers. The magnetic imaging details are given in table 1. 
Preoperative chemotherapy
CRT was not routinely given until December 2003 but seven patients received 
chemotherapy (5-FU/ leucovorin) as part of a randomized multicenter trial (Nordic 
LARCS-A Trial). After December 2003, 93% of the patients received 5-FU/ leucovorin 
(n=44) or oxaliplatin/ 5-FU/ leucovorin (n=9). The patients who received CRT in the last 
period were compared to those given RT in the first period.
Preoperative radiotherapy    
The RT was based on a CT dose planning system and the patients received a median 
of 50 Gy (50-64) preoperative RT; 46 Gy in 2 Gy fractions towards the pelvis and a 
boost of 4 Gy in two fractions towards the tumour. Seven patients received additional 
fractions of 1-12 Gy due to treatment discontinuity. 
Surgery
Total mesorectal excision technique (TME) was performed with extended dissection 
outside the mesorectal fascia to obtain “en bloc” resection of tumour and this was 
achieved in 95%. The procedure was often a joint venture by gastrointestinal surgeons, 
urologists and plastic surgeons. The surgical procedures were performed a median of 
56 days (36-119) after the end of RT and a median of 20 days (4-84) after MRI 
evaluation. Peroperatively it was often difficult to identify the surgical planes between 
tumour and surrounding organs. As it could not be definitely decided if the adherences 
were due to tumour tissue or fibrosis, even in patients with non-infiltration on yMRI, the 
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surgeon had to decide during the procedure whether to resect the whole or only a part 
of the affected organ. In some cases, previously undetected distant metastases were 
found during surgery and a less radical procedure performed in the pelvis. Resections of 
fascia or muscle fibres of the piriformis or obturator muscle were considered as 
resection of the pelvic wall. Resection of levator ani was performed as part of an 
abdominoperineal resection (APR) and in some patients the coccyx or part of the 
sacrum was resected as well.
Pathology 
Examination of removed specimens were performed according to the MERCURY 
protocol (10;11). The specimens were opened from the ends until 2 cm above/ below 
the tumour and fixed in formalin. The unopened area was cut in 5 mm slice thickness 
transversely and large-mount preparations were made of tumour slices that showed the 
maximum depth of penetration and with the tumour close to the circumferential 
resection margin (CRM). A histological complete response (ypT0) was achieved if the 
pathologist was unable to demonstrate any intact viable tumour cells within the 
operative specimen. The presence of mucin lakes without adjacent cells was defined as 
a complete response. TRG were analyzed and classified according to Bouzourene (16)
based on the presence of residual tumour cells and the extent of fibrosis. In Grade 1, 
there are no residual tumour cells and fibrosis extends through all the layers of the 
rectal wall. Grade 2 has rare residual tumour cells scattered throughout the fibrosis. 
Grade 3 involves more residual tumour cells but the fibrosis still dominates. Grade 4 
demonstrates residual tumour cells outgrowing the fibrosis whereas in Grade 5 there is 
lack of tumour regression. The same pathologist (KKG) with experience from the 
MERCURY study evaluated all but one specimen.
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Statistical analysis
Association between categorical variables were assessed using chi-square tests 
(Pearson and linear-by-linear). Differences between groups of quantitative variables 
were tested using Mann-Whitney test. The downstaging of T- and N-stages in Table 3 
were evaluated by the McNemar-Bowker Test of symmetry or McNemar Test. P values 
of 0.05 or less were regarded as significant. Calculations were performed using the 
Statistical Package for the Social Sciences® program, version 15.0 (SPSS, Chicago, 
Illinois, USA).
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RESULTS 
Ninety-two patients with T4a primary rectal cancer based on cMRI evaluation before 
neo-adjuvant treatment were included in this study and demographic data regarding 
resection status are given in Table 2. Evaluated by MRI, pelvic organs (uterus, vagina, 
bladder, vesicle and prostate) were affected in 32 patients, perirectal structures (pelvic 
muscles, nerves, vessels, sacrum and ureter) in 12 patients and both pelvic organs and 
perirectal structures in 48 patients. After neo-adjuvant treatment, a R0 resection was 
obtained in 73 patients (79%), a R1 resection in 16 patients (18%) and R2 resections in 
three patients (3%). All R2 resections and six of the R1 resections had distant 
metastases (inoperable liver, lung or lymphatic metastasis) at the time of surgery. In the 
remaining ten R1 resections the anatomical site of failure was on the pelvic wall in 
seven patients, the peritoneal reflection in two and the prostate in one patient. The latter 
was the only patient with an unintended R1 resection for infiltration of a pelvic organ and 
had peripheral resection of the prostate. If patients with known ir-resectable metastases 
were excluded from the study, a R0 resection rate was obtained in 63 of 74 patients 
(85%) and R1 resections in the rest of the patients.
There was no difference in age between the R0 and the R1/R2 resection groups. 
However, in females more R0 resections and no R2 resections were obtained (p<0.01). 
In 85% of patients who received CRT a R0 resection was obtained compared to 64% in 
patients who received only RT (p<0.05). The time from end of radiation therapy to 
surgery and the type of surgery performed were similar in the two groups. However, the 
mean length of the tumours after preoperative treatment was significantly larger in 
patients receiving a non-radical resection (p<0.01). More pelvic organ resections were 
performed in R0 patients (78% versus 42%, p<0.01 and more downstaging of N-status 
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occurred in the R0 resection group compared to R1/R2 resection group (58% versus 
21%, p<0.01). 
The effect of neo-adjuvant treatment on MRI based T and N staging is shown in Table 
3. After completion of neo-adjuvant treatment, downstaging from pT4a occurred in only 
9 of 92 patients (10%), and only to pT3. The pre-treatment N stage by cMRI was; 11 N0, 
17 N1 and 64 N2. MRI examinations after neo-adjuvant treatment showed an N-stage 
downstaging in 48 of 81 patients (59%) and 35 of 81 patients (43%) obtained a N0 
disease. Only one patient was upstaged (1%).
Five of the nine patients suggested by yMRI to be downstaged to T3 were further 
confirmed to be ypT3 tumours (Table 3). Of the other four, three were ypT0-2 tumours 
and one had an ypT4 tumour. Of the 83 patients determined by yMRI to be T4 tumours, 
only 32 were confirmed by pathological examination to be ypT4 tumours. Fifty-one 
patients had a downstaging at pathological examinations that was not detected by yMRI 
(55%).  Overall, similar staging by yMRI and histopathological evaluation was obtained 
in 40% of the patients.  By pathological evaluation, only five of the downstaged had 
received R1 resections, four because of microscopically involved CRM next to the 
tumour and one next to an infiltrated lymph node. 
Totally, in 37 patients the staging in MRI after neo-adjuvant treatment and the 
classification in histopathology were similar. However, in 51 patients (55%) the 
histopathology staged the patients as T0-T3 (38 ypT3, 5 ypT1-2 and 8 ypT0) even 
though MRI had staged the patient as T4.
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Histopathological evaluation revealed nine patients (10%) with a complete pathological 
response to neo-adjuvant treatment (ypT0) (Table 3). In a further 54% the primary 
tumour was located within the mesorectal fascia. Thus if we had performed an ordinary 
TME operation instead of an extended one, there would have been R1/ R2 resections in 
all 33 patients with ypT4 (36%) in addition to 7 R1 in the tumours within the mesorectal 
fascia (7%), totally 43%. This would have been more than the double of the 21% 
obtained after performance of ETME. 
Comparing N-staging by MRI after neo-adjuvant treatment with pathological 
examination as a reference standard showed that 47 of 92 (51%) were similarly staged 
by MRI, whereas 13 % were under-staged and 36% were over-staged by yMRI 
(Table3b). 37 of 45 patients (82%) with a MRI N0 stage after neo-adjuvant treatment 
had a confirmed histopathological ypN0 disease.
The relation between TRG and ypT-stage is shown in Table 4. Among the 33 ypT4 
tumours 18 were TRG2-3 and 15 were TRG4-5 demonstrating that we found tumour 
cells outside the mesorectal fascia scattered within fibrosis in as much as 55% of the 
ypT4 group. All the tumours resulting in an ypT1-2 had TRG2-3, whereas all ypT3-4 
tumours had TRG2-5 (p<0.01). Preoperative CRT resulted in a higher percent of 
patients obtaining a TRG1-3 compared to patients receiving RT (79% vs 57%, p=0.02) 
(Table 5). 
In spite of the modest T downstaging on MRI, a reduction in length of tumour of more 
than 30% was achieved by neoadjuvant treatment in 45% of the tumours (17).
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The relation between yMRI infiltration and up-/downstaging from cMRI, performed 
surgery and infiltration of organs and structures are given in table 6. Threatened tumour 
infiltration after neo-adjuvant treatment was described by the yMRI examination in 89 
pelvic organs, in 22 cases on the pelvic wall and in 36 cases on the pelvic floor. Surgery 
was performed on 70 of the pelvic organs with threatened infiltration on MRI ( 1mm 
distance to organ), including all ten bladders but no more than 14 of 21 affected vaginas 
and 14 of 19 prostates. The infiltration was confirmed by pathological examination in 23 
pelvic organs and, in addition, fibrosis or mucus in the organs was found in 15 pelvic 
organs. Totally, signs of infiltration into pelvic organs were confirmed by 
histopathological examination in a large proportion where yMRI had documented 
threatened margins: bladder (90%), vagina (71%), seminal vesicles (50%) and prostate 
(43%).  
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DISCUSSION    
The definition of LARC varies and some include any T-stage with N+ disease. We have 
included only patients with T4a cancers that on cMRI infiltrated into surrounding pelvic 
organs. Thus, the tumours in our patients have a more extensive growth than in most 
other studies on this topic. Although MRI is considered the best method for examination 
of LARC, in a material without neo-adjuvant treatment, the accuracy of organ infiltration 
measured by yMRI was 80% judged by the pathology examination of the removed 
specimen (18). To reduce inter-individual differences, colleagues with experience from 
the previous MERCURY study performed the MRI and pathology examinations.
During our study period the clinical value of the yMRI had not been clarified and in some 
cases the tumour shrinkage following neo-adjuvant treatment lead the surgeon to 
perform a less extensive resection than cMRI indicated. 
A few prospective studies as well as retrospective audits have focused on MRI and 
histopathologic assessment of the specimen in rectal cancer surgery, irrespective of 
tumour stage (3;9-11;19-21). MRI in LARC before neo-adjuvant treatment compared to 
the removed specimen has been the focus of few reports (19;22;23) or when being 
addressed contained a very small proportion of mrT4 tumours (21;24-28). In one study 
LARC and recurrent rectal cancer were evaluated together (18) but no study to our 
knowledge has tried to evaluate the clinical importance of the preoperative MRI after 
neo-adjuvant treatment or TRG data from a relatively large number of MRI diagnosed 
T4 tumours.
Resection margins and resection status
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MRI’s ability to demonstrate signal differences between different soft tissues are 
important to discriminate between structures on the pelvic sidewall as well as to detect 
tumour invasion. Accordingly, MRI is considered the superior tool in predicting the CRM 
status by TME, depth of extramural tumour and nodal status (9-11). In T4a rectal 
tumours, however, the mesorectal fascia is involved by tumour, and surgery must be 
extended beyond the TME plane. MRI predicted clear resection margins in 98% R0 
resections of patients given RT or CRT in the MERCURY study, but predicted no more 
than 44% of the patients when only R1/R2 resections were achieved (11). 
There was only one R1 resection after performance of total prostatectomy in 17 
patients. However, all five cases with a partial resection of the prostate resulted in a R1 
resection. The failure against the pelvic wall in four of five and distant metastases in 
three reduced the willingness to extensive and mutilating local procedures. 
Histopathological proven infiltration in a pelvic organ or the pelvic wall was found in 21 
patients and 14 of them were classified as R0 resection. Without an extended TME 
these patients would have been left with tumour tissue. In addition, a substantial number 
of patients, which is difficult to estimate precisely, would have been left with a minimal 
distance to tumour tissue (1 mm) resulting in a R1 resection. However, in patients with 
a short life expectancy as in disseminated disease, co-morbidity or very high age, 
performance of an ordinary TME instead of the extended TME could be the best 
solution. This might even be the case in large tumours threatening the lateral margins in 
multiple areas where potential extended procedures might lead to high risk of a non-
radical resection and reduced quality of life.  
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Local recurrence rate is inversely related to the CRM and  1mm or  2mm lateral 
margins in the specimen have been advocated (2;4;29). MRI evaluated, margins  1mm 
(11) or  2mm (12) been considered as threatened lateral margins of non-T4 cases. 
Neither the necessary margins nor the need for removal of entire compartments are 
known when the tumour infiltrates adjacent organs or structures.
T downstaging  
We found 10% T downstaging evaluated by cMRI and yMRI, not unlike 17% observed 
by Allen (26) in a small study on 30 patients including only nine cmrT4 patients. In 
contrast, Baatrup et al found downstaging in seven of fourteen cmrT4 cases after 60 Gy 
preoperative CRT with 5-FU (30). In our study, the total accuracy detected by yMRI was 
only 40% and overstaging in 59% of the cases with pathology as a reference standard. 
These results are not unlike the report from Kuo on 14 T4 tumours given neo-adjuvant 
treatment (19) with 47% total accuracy of yMRI compared to histological examination. 
They report all ypT4 correctly staged, however ypT0, ypT1, ypT2, ypT3 were 
overstaged in 80%, 100%, 57% and 30%, respectively. 
Due to the problem of detecting islets of viable tumour within fibrosis or mucin deposits, 
our radiologists have interpreted the fibrosis/ mucin as possibly containing tumour 
leading to a low proportion of downstaging in T-stage. However, our results with a total 
downstaging in T4a level from cMRI to final pathology of 64% is similar to reported in 
small series of 22 and 18 T4 tumours (73%-76%)  (3;22). 
The discrepancy between yMRI and the evaluation of the specimen could also be 
explained by further downstaging of tumour due to the time lag between MRI and 
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surgery. However, the median time to surgery was not more than 20 days and only five 
patients waited more than six weeks. Vliegen recently showed a substantial overstaging 
of tumour invasion in the mesorectal fascia in yMRI, which occurred in 36% and 22% of 
cases by two dedicated observers (12), demonstrating the inter-individual differences in 
evaluation.
N downstaging
By preparation of the specimen we routinely leave the mesorectum intact during fixation. 
A higher yield of lymph nodes might have been obtained if the mesorectum was 
squeezed for lymph nodes in the unfixed state. On the other hand, our application of the 
recently suggested important characteristics for lymph nodes, like irregular borders and 
signal intensity characteristics by MRI, in addition to general morphological criteria such 
as size and shape of the node might influence the number of metastatic nodes detected 
by MRI (15;31). 
mrN downstaging after the neo-adjuvant treatment as evaluated by yMRI was seen in 
70% of the patients. yMRI N downstaging was also observed even when the primary 
tumour was not decreased in size or stage. Our result is similar to 64% and 68% 
previously reported (19;26). The accuracy between MRI after neo-adjuvant treatment 
and the final histopathology was 51% whereas MRI overstaging was 36% and 
understaging 13%. Understaging could be explained if pathological lymph nodes were 
not removed surgically or not detected by the pathologist. In 43% of the patients a N0 
disease, evaluated by MRI, after CRT was obtained which is similar to 46% reported 
after CRT in a LARC study with only 8% mrT4 cases (24).
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TRG, fibrosis and yMRI-assisted histopathology 
Our radiologists have interpreted the fibrotic scar as possibly containing tumour, 
presuming that small islets of tumour cells would not make any visible difference of the 
MRI-signal. Within a voxel (the smallest imaging element), the dominating tissue will 
determine the signal. According to the dominance of fibrosis in TRG2-3, the yMRI signal 
from scattered tumour cells within fibrosis will be that of fibrosis. The signal from tumour 
cells will not be enough to alter the signal of the whole voxel, in contrast to the situation 
before treatment where tumour cells usually are densely organized and not scattered. 
Hence cMRI will more accurately demonstrate the presence of tumour. If tumour cells 
and fibrosis were more separated as in TRG4-5, the signals might be discriminated and 
therefore TRG4-5 is more obviously recognized due to less fibrosis.
We would expect that all 83 ymrT4 cases could result in a local recurrence if only a TME 
had been performed. However, 51 of these had a histopathological stage less than 
ypT4, and therefore no verified tumour outside the mesorectal fascia even though the 
yMRI suggested so. Eight of them were TRG1, 24 TRG2, seven TRG3 and 12 TRG4 
suggesting that the majority of the tumours contained mostly fibrosis. Accordingly, the 
39 patients with TRG1-3 can be very difficult to classify histopathologically due to the 
amount of tumour with a large critical margin laterally. CRT induced fibrosis, necrosis 
and mucus in the tissue which produced difficulties in evaluating resected organs, 
structures and the status of the resection margins. 
We presume that a MRI assisted technique for the pathological investigation of the 
areas at risk in an optimal histopathological slide can be of great value in discovering 
small nests of tumour tissue outside the mesorectal fascia (Figure 1). This could be 
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important for future staging and planning of treatment. We will later address the results 
with this new technique from an ongoing study.
Brown et al found the discrimination of tumour from radiation-induced fibrosis so difficult 
by yMRI after long course RT that they were not able to measure the depth of 
extramural spread and therefore excluded all six patients with this treatment (32). They 
also suggested it likely to be more useful to compare pre-treatment MRI (cMRI) with 
histopathology of the resected specimen to determine the extent of tumour regression. 
Our TRG1-3 frequency of 70% is higher than 59% reported by Bouzourene in their 
study with only RT as neo-adjuvant treatment for LARC (16). The difference can be due 
to our inclusion of 53 patients given preoperatively CRT (58%) which was found to 
improve the TRG grades.
In a published abstract, scattered tumour cells within the fibrosis, at or outside the 
mesorectal fascia were reported in 50% of pT4 tumours treated with RT or CRT (13)
which is similar to our 55% of TRG2-3 in this group. These observations strengthen the 
need for surgical resection of all fibrosis in locations where MRI before treatment 
showed tumour to obtain optimal results. There has been a tendency over the last years 
to perform an increasing rate of low anterior resections (LAR’s) in advanced rectal 
cancer (33). The results show that fibrosis left in situ in advanced cases may contain 
viable tumour cells, which may increase the late recurrences. In this way, the reported 
28% local relapses after RT occurring more than 5 years after surgery could be 
explained (34). Thus a longer observation interval may be necessary to determine the 
true local recurrence rate after CRT.
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The histopathological complete response rate (ypT0) after neo-adjuvant CRT vary with 
the type of chemotherapy added to the RT, the selection of patients, the proportion of T-
stages and also with the irradiation regimen (8;35;36). We found 10% histological 
proven complete response in our study of only T4a tumours. The proportion may be 
increased by addition of induction chemotherapy with new drugs (22;37) and the 
downstaging and downsizing of tumour may lead to less extensive resections in the 
future.
Reduction in tumour size 
Our study shows reduction in length of tumour after neo-adjuvant treatment measured 
by MRI, and further reduction of maximal tumour diameter evaluated in the specimen. 
Because the maximal tumour diameter is a measure of axial growth of the tumour, it is 
not surprising that we found it to be a marker for R1/ R2 resections and for advanced T 
stages. Torkzad et al (25) showed a clear correlation between tumour volume and 
percent volume reduction after RT by MRI and histopathology. Kim et al (38) reported a 
significant difference in tumour volume and percent volume reduction rates between 
patients whose tumours were downstaged and those that were not in a study with 4% 
T4 tumours. Tumor size is a factor known to influence histopathological downstaging of 
rectal cancer after CRT. Decrease in tumour size, according to the RECIST criteria of 
more than 30% occurred in 41 of our patients (45%) (17). Allen et al (26) found a 
decrease of more than 30% in tumour size in 63% of cases, but their report contains 
only nine T4 tumours, and in addition 19 T3 and two T2 tumours. A recently published, 
small study with 28% T4 tumours did not find that a reduction in tumour volume was a 
marker for N downstaging or TRG (39).
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Infiltration of organs/ structures
The area of failure after intentional curative resection was the pelvic wall in seven of our 
ten R1 resections (70%) with M0 disease. In six of seven cases we had signs of 
threatened organ infiltration on MRI both before and after neo-adjuvant treatment and in 
five of seven after neo-adjuvant treatment. Five of the seven patients had yMRI 
classified pathological lymph nodes on the pelvic wall. Among the ten failures, there 
were only two women.  The explanation to this might be the wide female pelvis, where 
the vagina/ uterus often is a barrier for further spread in the anterior direction, and 
therefore is easier to eradicate than the narrow male pelvis (7).  
MRI is still the most accurate modality in demonstrating involvement of neighbouring
organs. The MRI evaluated threatened organ and structure infiltrations, before and after 
neo-adjuvant treatment, corresponds to surgery on performed pelvic organs. yMRI 
showed threatened infiltration (growing into organ or structure or  1 mm of organ or 
structure) in 89 pelvic organs. Peroperatively we resected 70 and evaluated the 
remaining 19 as not infiltrated. Only in 34%, we were able to confirm the tumour cells in 
the organ, but in another 15 patients (21%), we found fibrosis as sign of infiltration 
before neo-adjuvant treatment. 
Should findings in MRI after CRT/ RT alter the operative strategy?
The tissue reaction to neo-adjuvant treatment makes yMRI difficult to evaluate. Videhult 
et al reported that among patients with no agreement between ymrCRM and ypCRM, 
half of them received long course RT (20). Fibrosis possibly containing scattered tumour 
cells might be handled in two ways; resected or left in situ. The first option would lead to 
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a more, and sometime needlessly extended operation, probably also with permanent 
diverting stoma whereas the latter might leave tumour cells in the pelvis, probably 
resulting in more cases of local relapse after some years.
In some cases the repeat MRI after CRT clearly shows retraction of pathological tissue 
from structures thought to be infiltrated or adjacent to tumour on MRI before CRT, thus 
showing overstaging/ misinterpretation of the tumour in the first place. In these cases, 
the repeat MRI of course might alter the operative strategy. 





























































For Peer Review Only
22
CONCLUSION
Radiological assessment with MRI of the pelvis identifies patients in need of neo-
adjuvant treatment in LARC. Eighty-five percent R0 resections were obtained in M0 
patients after MRI diagnosed infiltration into adjacent organs (cmrT4a). ETME was 
performed in 95% of the patients, mostly as en-bloc resections. However, the non-
radical resections were not predicted in advance and the remaining tumour tissue were 
nearly always located on the pelvic wall. 
MRI after neo-adjuvant treatment did not predict downstaging satisfactorily and in 
patients with histopathology proven T4, fibrosis with scattered tumour cells remained in 
the 18 patients (55%) with TRG2-3. Therefore, surgery should be performed in 
accordance with the pre-treatment MRI to obtain optimal result. Otherwise, late 
recurrence may develop from scattered tumour cells within the fibrosis that might be left 
in situ. MRI after end of neo-adjuvant treatment gives little new information for planning 
of surgery, and is mostly important in discovering disease progression.
In the future, more effective CRT protocols may reduce the need for ETME operation 
due to increased downstaging of tumour. The study has initiated a new approach to 
histopathological classification of the removed specimen where we introduce a MRI 
assisted technique for investigating the areas of risk outside the mesorectal fascia in the 
specimen. 
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Table 1. Details of the MRI used in the study.
Parameter Sagittal  Sagittal FSE Axial FSE T2W: 
From pelvic floor 
to promontorium




Field of view 20 cm 20 cm 20 cm 16 cm
Slice thickness 4 mm 5 mm 5 mm 3 mm
Intersection gap 1 mm 1 mm 1 mm 0 mm
Matrix  256 x 256  256 x 256  256 x 256  256 x 256
TE (Echo time) 85 ms 85 ms minimum 85 ms
TR (Repetition time)  3000 ms  3000 ms 400-700 ms  3000 ms
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Table 2. Patient - and treatment characteristics regarding R status.
Parameter R0 resection (n=73) R1-2 resection (n=19)
n or 
median
range n or 
median
range P value
























Age year 60.5 23-82 67 29-81 p=0.333
Operation after 
radiotherapy
days 56 36-119 55 39-113 p=0.253
Maxiamal tumour 
diameter 
(mm) 40 0-110 60 35-170 p<0.013




















































cMRI length  of tumour mm 79 32-140 92 50-150 p=0.083
yMRI length  of tumour mm 48.5 0-130 67 10-130 p=0.013
MRI  reduction of 
tumour length  















































































1Pearson Chi-Square; 2Linear-by-linear; 3Mann-WhitneyTest 
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Table 3a. MRI-evaluated T- and N stages before - and after CRT/ RT.
MRI-evaluated T-stages pre-CRT vs. post-CRT
ymrT0 ymrT1-2 ymrT3 ymrT4 Total
mrT4 0 0 9 83 92
MRI-evaluated N-stage pre-CRT vs. post-CRT  
ymrN0 ymrN1 ymrN2 Total
mrN0 10 0 1 11
mrN1 11 6 0 17
mrN2 24 13 27 64
Total 45 19 28 92
p<0.01, McNemar-Bowker Test.
Table 3b. MRI-evaluated T- and N stages after CRT/ RT versus pathology.
T-stages post-CRT vs. histology 
ypT0 pT1-2 ypT3 ypT4 Total
ymrT3 1 2 5 1 9
ymrT4 8 5 38 32 83
Total 9 7 43 33 92
p<0.01, McNemar Test.
N-stages post-CRT vs. histology 
ymrN0 ymrN1 ymrN2 Total
ypN0 37 11 18 66
ypN1 6 4 4 14
ypN2 2 4 6 12
Total 45 19 28 92
p<0.01, McNemar-Bowker Test.
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Table 4. Tumour regression grade and histopathologic stage (16).
Histopathologic 
stage
TRG1 TRG2-3 TRG4-5 Total
ypT0 9 0 0 9
YpT1-2 0 7 0 7 
ypT3 0 30 13 43
ypT4 0 18 15 33
Total 9 55 28 92
p<0.01, linear-by-linear.
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Table 5. Tumour regression grade and preoperative treatment (16)
TRG1 TRG2-3 TRG4-5 Total
CRT 5 37 11 53
RT 1 15 12 28
Total 6 52 23 81
p= 0.04, linear-by-linear.
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Bladder 10 2 4 10 6 3 1
Vesicula 
seminalis
25 1 0 20 7 3 10
Prostate 19 2 3 14 3 3 8
Vagina 21 1 3 14 5 5 4
Uterus 10 0 0 9 1 1 7
Small bowel 4 0 2 2 1 1
m. puborectalis/ 
m. levator ani





22 3 3 19 1 - -
Threatened organ- or structure infiltration on MRI: Tumour evaluated as growing into 
organ or structure or  1 mm of organ or structure.
Histopathological infiltration: Vital tumour cells found in adjacent organ or structure.
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Figure 1. Tumour islets within mucinous infiltration (black arrowheads) of the uterine 
cervical stroma. (a) Resection specimen slice. (b) Corresponding transversal T2-weighted 
MRI obtained after radiation theraphy. (c) Corresponding whole-mount histology 
(haematoxyline and eosine stained). Four islets of tumour where present (red circles). 
(d) Original magnification x 25 of the largest tumour deposits (white arrowhead).  
99x102mm (300 x 300 DPI)  
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